Hyperliquid Strategies completes business combination with Sonnet BioTherapeutics
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- S&P 500, Dow rise on Mideast deal hopes, SpaceX's historic debut
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Oil nears two-month lows on reports of imminent US-Iran peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Super Micro Computer establishes $1.25 billion stock sale agreement
Hyperliquid Strategies Inc and Sonnet BioTherapeutics Holdings, Inc. Announce Closing of Business Combination
December 2, 2025 4:30 PM ESTHyperliquid Strategies Common Stock Expected to Begin Trading on Nasdaq on Wednesday, December 3 Under the Ticker PURR
NEW YORK and PRINCETON, N.J., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Hyperliquid Strategies Inc (HSI or the Company) and Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN) (Sonnet) today announced the completion of the closing of the previously announced business combination among HSI, Sonnet and Rorschach I LLC (Rorschach), a newly-formed entity formed by an entity affiliated with Atlas Merchant Capital LLC (Atlas), an affiliate of Paradigm Operations LP (Paradigm), and additional sponsors (all together, the Sponsors), which was approved by Sonnets... More
